All Agenda Items at BioNTech SE’s 2026 Annual General Meeting Are Approved by Shareholders

(SeaPRwire) –   MAINZ, Germany, May 15, 2026 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) convened its Annual General Meeting (“AGM”) today. A total of 92% of the share capital was represented at the virtual meeting. All resolutions put forward on the agenda items were approved by a majority of shareholders.

BioNTech is intensifying its focus on the Company’s expanding late-stage oncology pipeline while continuing discovery and early research efforts aimed at long-term innovation. As a result, shareholders have approved increasing the Supervisory Board from six to eight members and adding new expertise: Prof. Iris Löw-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new Supervisory Board members.

Iris Löw-Friedrich brings extensive experience in clinical development and broad expertise across scientific and medical fields. She also holds knowledge in sales and commercialization, management, innovation, and international markets relevant to the Company.
She serves as an experienced Supervisory Board member and adjunct professor of internal medicine at Goethe University Frankfurt am Main’s Faculty of Medicine.

Susanne Schaffert is a supervisory board member in the healthcare sector, including at Merck KGaA. She has specialized expertise in oncology, as well as in sales and commercialization with a strong focus on product launches. Her background encompasses innovation, research and development, and organizational leadership and management.

Additionally, shareholders approved renewing the mandates of BioNTech’s Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph.D., and Prof. Rudolf Staudigl, Ph.D.

Following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman during a subsequent session.

The voting results for all agenda items are available on the Annual General Meeting 2026 website under the ‘Voting Results’ section. The speeches delivered by Chief Executive Officer Prof. Ugur Sahin, M.D., Chief Financial Officer Ramón Zapata, and the presentation slides from AGM 2026 can be accessed in the ‘Speeches and Presentations’ section via the same link.

About BioNTech
BioNTech is a global next-generation biopharmaceutical company focused on pioneering novel investigational therapies for cancer and other serious diseases. In oncology, the Company is dedicated to transforming cancer treatment approaches. Its goal is to develop innovative medicines with broad-tumor or synergistic effects to address cancer comprehensively across all stages—from early to late-stage disease. The Company’s growing late-stage oncology pipeline includes complementary therapeutic strategies covering immunomodulators, antibody drug conjugates, and mRNA-based cancer immunotherapies. BioNTech collaborates with multiple global and specialized pharmaceutical partners to leverage shared expertise and resources, accelerating innovation and progress—including partnerships with Bristol Myers Squibb, Duality Biologics, Genentech (a member of the Roche Group), Genmab, MediLink, OncoC4, and Pfizer.

For more information, visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding the potential benefits of newly appointed Supervisory Board members. In some cases, forward-looking statements may be identified by terms such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements included herein reflect BioNTech’s current expectations and beliefs concerning future events and are neither promises nor guarantees. Readers should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors—many beyond BioNTech’s control—that could materially affect actual results and cause them to differ significantly from those expressed or implied by these statements.

Risks and uncertainties are detailed under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These forward-looking statements are valid only as of the date hereof. Unless required by law, BioNTech undertakes no obligation to update or revise any forward-looking statements contained herein due to new information, future developments, or otherwise.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de